Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial
British Journal of Dermatology · 17.10.2025 · 193 (5) · 865-875
DOI: 10.1093/bjd/ljaf303 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Dermatology, online erschienen am 26.07.2025. Verfasst von Jürgen C Becker und 16 weiteren Autor:innen. Beteiligte Einrichtung: Translational Skin Cancer Research, West German Cancer Centre, Essen, Germany. Hauptthemen laut MEDLINE: Cetuximab, Skin Neoplasms, Carcinoma, Squamous Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Merck.
Abstract (Originalsprache)
Background
In cutaneous squamous cell carcinoma (cSCC), programmed cell death protein 1 (PD-1) and epidermal growth factor receptor (EGFR) inhibitors are effective in a considerable proportion of patients. However, there is an unmet medical need for patients with perianogenital cSCC or cSCC refractory to PD-1 therapy.
Objectives
To evaluate the combination avelumab (programmed death ligand 1 inhibitor) and cetuximab (EGFR inhibitor) in people with advanced cSCC treated for up to 1 year.
Methods
This multicentre phase II trial enrolled patients with advanced cSCC (prior systemic therapy allowed) to receive avelumab (10 mg kg–1 Q2W) plus cetuximab (500 mg m–2 Q2W) for up to 1 year. The primary endpoint was objective response. Predefined subgroups were line of therapy and localization of the primary tumour (perianogenital/other locations).
Results
Of 52 enrolled patients, 49 received at least 1 treatment dose. Of these patients, 20 achieved an objective response [41%, 95% confidence interval (CI) 27–56; 9 partial responses/11 complete responses (CRs)]. While treatment-naïve patients (n = 35) achieved a higher objective response rate (46%, 95% CI 29–63) than those who were pretreated (29%, 95% CI 8–58), 4 of 14 pretreated patients experienced an objective response, 2 with prior PD-1 inhibition. Five of 14 patients with perianogenital cSCC achieved an objective response (36%, 95% CI 13–65), including 4 CRs. At a median follow-up of 35 months, median progression-free and overall survival were 8.4 and 23.1 months, respectively. Grade 1 and 2 treatment-related adverse events (TRAEs) were common, while grade ≥ 3 events occurred in only 10 patients (20%) and 7 experienced serious TRAEs (14%); 2 discontinued treatment due to drug-related toxicity. Notably, quality of life improved, especially in patients with perianogenital primaries.
Conclusions
Avelumab in combination with cetuximab demonstrates encouraging clinical activity in advanced cSCC, including patients with challenging subgroups such as perianogenital primaries or those with disease that has progressed on anti-PD-1 monotherapy. This is especially true when patients are carefully selected for their ability to undergo treatment for at least 12 weeks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Skin Cancer Research, West German Cancer Centre, Essen, Germany.
- Department of Dermatology, University Hospital Essen, Essen, Germany.
- German Cancer Consortium (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
- Centre for Dermatooncology, Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
- Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
ORCID-Profile: Jürgen C Becker, Lisa Zimmer, Mirjana Ziemer, Bastian Schilling, Thomas K Eigentler, Elisabeth Livingstone, Selma Ugurel, Ralf Gutzmer
Förderung
- Merck
Zitieren
APA
Becker, J. C., Gesierich, A. H., Leiter, U., Zimmer, L., Hassel, J. C., von Wasielewski, I., Ziemer, M., Fluck, M., Meier, F., Spillner, A. N., Schilling, B., Eigentler, T. K., Livingstone, E., Ugurel, S., Angela, Y., Windemuth-Kieselbach, C., & Gutzmer, R. (2025). Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial. British Journal of Dermatology, 193(5), 865-875. https://doi.org/10.1093/bjd/ljaf303
Vancouver
Becker JC, Gesierich AH, Leiter U, Zimmer L, Hassel JC, von Wasielewski I, et al. Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial. British Journal of Dermatology. 2025;193(5):865-875. doi:10.1093/bjd/ljaf303
BibTeX
@article{Becker2025,
author = {Becker, Jürgen C and Gesierich, Anja H and Leiter, Ulrike and Zimmer, Lisa and Hassel, Jessica C and von Wasielewski, Imke and Ziemer, Mirjana and Fluck, Michael and Meier, Friedegund and Spillner, Alexandra N and Schilling, Bastian and Eigentler, Thomas K and Livingstone, Elisabeth and Ugurel, Selma and Angela, Yenny and Windemuth-Kieselbach, Christine and Gutzmer, Ralf},
title = {Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial},
journal = {British Journal of Dermatology},
year = {2025},
volume = {193},
number = {5},
pages = {865--875},
doi = {10.1093/bjd/ljaf303}
}
EUVIMED